18. An isolated host cell transfected, transformed or transduced with the expression system of any one of claims 12-17.

19 The host cell of claim 18, which is selected from the group consisting of CHO, VERO, BHK, HeLa, Cos, MDCK, 293, 3T3, a myeloma cell line, and WI38 cells.

20. A method of producing a heteromeric complex comprising the step of culturing the host cell of claim 19 under conditions wherein the heteromeric complex is expressed by the host cell.

21. The method of claim 20, further comprising isolating the heteromeric complex.

22. An expression system comprising a first vector comprising a first nucleic acid encoding a heavy chain of an antibody operably linked to a second nucleic acid that encodes an N-terminal mutant glutamine synthetase (mutGS-NT), and a second vector comprising a third nucleic acid encoding a light chain of an antibody operably linked a fourth nucleic acid that encodes a C-terminal mutant glutamine synthetase (mutGS-CT), wherein the mutGS-NT comprises two or more mutations selected from the group consisting of W60A N61A D63A D63R S66A and D76A and the mutGS-CT comprises one or more mutations selected from the group consisting of E134A E136A E196A E203A N248A H253A N255A R319A and R324A wherein each mutant subunit of glutamine synthetase does not have selectable activity when expressed alone and co-expression of the mutGS-NT with the mutGS-CT provides glutamine synthetase activity, wherein the expression system is capable of being transfected into mammalian cells.

23. The expression system of claim 22, wherein the mutGS-NT is selected from the group consisting of W60A N61A D63A (mutGS-NT1; SEQ ID NO:6), W60A N61A D63A S66A (mutGS-NT2; SEQ ID NO:10) W60A N61A D63A S66A D76A (mutGS-NT3; SEQ ID NO:25), and W60A N61A D63R S66A (mutGS-NT4; SEQ ID NO:19); and the mutGS-CT is selected from the group consisting of E134A E136A E196A E203A (mutGS-CT1; SEQ ID NO:21) and N248A H253A N255A (mutGS-CT2; SEQ ID NO:22).

24. An isolated host cell transfected, transformed or transduced with the expression system of claims 22 or 23.